Loading [a11y]/accessibility-menu.js
Editöre Mektup
BibTex RIS Kaynak Göster

The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions

Yıl 2020, Cilt: 3 Sayı: 3, 81 - 83, 31.12.2020

Öz

COVID-19 is a new Coronavirus disease that researchers have reported older age, male gender, and comorbidity are associated with a higher risk of severe disease and mortality. Unfortunately, there is no sufficient supporting evidence that any potential therapy improves outcomes in patients diagnosed with COVID-19. Currently, one of the most popular potential treatment options is hydroxychloroquine. However, it also has serious adverse effects (<10%), including QTc prolongation with a possible risk of torsades de pointes, hypoglycemia, neuropsychiatric effects, and retinopathy. Therefore, careful monitoring is required during hydroxychloroquine treatment, and there is an urgent need to develop safe and effective drugs to treat COVID-19 potentially.

Proje Numarası

yok

Kaynakça

  • 1. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American journal of Chinese medicine. 2020 Mar; 13:1-26.
  • 2. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: a single-center experience in Turkey between 2013 and 2017. Clinical interventions in aging. 2018; 13:1899-1905.
  • 3. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 May; 323(18):1824-1836.
  • 4. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun ;8(6):539-541.
  • 5. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun; 382(25):2411-2418.
  • 6. Dixon DL, Van Tassell BW, Vecchie A, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of cardiovascular pharmacology. 2020 May;75(5):359-367.
  • 7. https://www.covid19-druginteractions.org/. Accessed in 6th July 2020.
  • 8. Lexicomp® Drug Interactions. https://www.uptodate.com/drug-interactions/#di-druglist. Accessed in 7th July 2020.
  • 9. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed in 6th July 2020.
  • 10. U.S. Food & Drug Administration News Release: Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed in 18th June 2020.

Yaşlı COVID-19 Hastalarında Tedavinin Güçlükleri ve Potansiyel İlaç Etkileşimleri

Yıl 2020, Cilt: 3 Sayı: 3, 81 - 83, 31.12.2020

Öz

COVID-19, araştırmaların ileri yaş, erkek cinsiyet ve komorbiditenin daha şiddetli hastalık ve ölüm riski ile ilişkili olduğunu bildirdiği yeni bir koronavirüs hastalığıdır. Ne yazık ki, herhangi bir potansiyel tedavinin COVID-19 teşhisi konan hastalarda sonuçları iyileştirdiğine dair yeterli destekleyici kanıt yoktur. Şu anda en popüler potansiyel tedavi seçeneklerinden biri hidroksiklorokindir. Ancak hidroksiklorokin, QTc uzaması ile birlikte olası torsades de pointes riski, hipoglisemi, nöropsikiyatrik etkiler, retinopati gibi ciddi yan etkilere (<% 10) neden olabilmektedir. Bu nedenle, hidroksiklorokin tedavisi sırasında dikkatli izlem gereklidir ve COVID-19'u tedavi etme potansiyeline sahip güvenli ve etkili ilaçların geliştirilmesine acil ihtiyaç duyulmaktadır.

Destekleyen Kurum

yok

Proje Numarası

yok

Teşekkür

yok

Kaynakça

  • 1. Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American journal of Chinese medicine. 2020 Mar; 13:1-26.
  • 2. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: a single-center experience in Turkey between 2013 and 2017. Clinical interventions in aging. 2018; 13:1899-1905.
  • 3. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 May; 323(18):1824-1836.
  • 4. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun ;8(6):539-541.
  • 5. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun; 382(25):2411-2418.
  • 6. Dixon DL, Van Tassell BW, Vecchie A, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of cardiovascular pharmacology. 2020 May;75(5):359-367.
  • 7. https://www.covid19-druginteractions.org/. Accessed in 6th July 2020.
  • 8. Lexicomp® Drug Interactions. https://www.uptodate.com/drug-interactions/#di-druglist. Accessed in 7th July 2020.
  • 9. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed in 6th July 2020.
  • 10. U.S. Food & Drug Administration News Release: Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed in 18th June 2020.
Toplam 10 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm Makaleler
Yazarlar

Esra Ateş Bulut 0000-0002-1124-9720

Pinar Soysal 0000-0002-6042-1718

Ahmet Turan Işık 0000-0001-5867-6503

Proje Numarası yok
Yayımlanma Tarihi 31 Aralık 2020
Gönderilme Tarihi 12 Ekim 2020
Kabul Tarihi 15 Aralık 2020
Yayımlandığı Sayı Yıl 2020 Cilt: 3 Sayı: 3

Kaynak Göster

APA Ateş Bulut, E., Soysal, P., & Işık, A. T. (2020). The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. Geriatrik Bilimler Dergisi, 3(3), 81-83.
AMA Ateş Bulut E, Soysal P, Işık AT. The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. GBD. Aralık 2020;3(3):81-83.
Chicago Ateş Bulut, Esra, Pinar Soysal, ve Ahmet Turan Işık. “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”. Geriatrik Bilimler Dergisi 3, sy. 3 (Aralık 2020): 81-83.
EndNote Ateş Bulut E, Soysal P, Işık AT (01 Aralık 2020) The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. Geriatrik Bilimler Dergisi 3 3 81–83.
IEEE E. Ateş Bulut, P. Soysal, ve A. T. Işık, “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”, GBD, c. 3, sy. 3, ss. 81–83, 2020.
ISNAD Ateş Bulut, Esra vd. “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”. Geriatrik Bilimler Dergisi 3/3 (Aralık 2020), 81-83.
JAMA Ateş Bulut E, Soysal P, Işık AT. The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. GBD. 2020;3:81–83.
MLA Ateş Bulut, Esra vd. “The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions”. Geriatrik Bilimler Dergisi, c. 3, sy. 3, 2020, ss. 81-83.
Vancouver Ateş Bulut E, Soysal P, Işık AT. The Challenges of COVID-19 Treatment in Older Patients and Potential Drug Interactions. GBD. 2020;3(3):81-3.

Creative Commons Lisansı

Bu dergide yayınlanan makaleler Creative Commons Atıf-GayriTicari-AynıLisanslaPaylaş 4.0 Uluslararası Lisansı ile lisanslanmıştır.


Geriatrik Bilimler Dergisi, Türkiye Atıf Dizini, Türk MEDLINE, Asos İndeks, Scilit, EuroPub ve Eylül 2022 tarihinden itibaren Index Copernicus International - Journals Master List ve 2023 sayıları itibariyle ULAKBİM TR-DİZİN'de indekslenmektedir.

download     |  download   | 24435    |        |   24370   

  24026     |    17423    |    scholar_logo_64dp.png     |     24050